Mircera is also indicated to treat CKD-associated ... administration and is supplied in single-dose prefilled syringes (30mcg/0.3mL, 50mcg/0.3mL, 75mcg/0.3mL, 100mcg/0.3mL, 120mcg/0.3mL, 150mcg ...

ZURICH (MarketWatch) -- Roche Holding AG RHHBY expects to soon launch anemia drug Mircera globally for use in chronic kidney disease, said Dan Kemmler, commercial director for the treatment ...

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically ...

Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring U.S. sales of the anemia med, claiming that Mircera doesn't infringe on Amgen's ...

Here's the action so far: A court ruled that Roche's anemia drug Mircera infringes on Amgen's patents on Epogen. But though Young granted Amgen's request for a temporary injunction against Roche's ...

The FDA delayed an approval decision on Roche’s Mircera pending a fall advisory committee review, spelling temporary relief for marketers of similar biologics.Mircera, an experimental treatment for ...

Mircera has been designed to treat anaemia associated with chronic kidney disease. Mircera is a new long-acting chemically synthesized erythropoiesis-stimulating agent. When approved by the ...

The FDA has approved Roche's anemia drug Mircera, but don't look for any big new product launches soon. Last month Amgen won a patent infringement case on the therapy. And Roche is studying its ...

Amgen Inc. said a federal court granted the biotechnology company a permanent injunction prohibiting Roche Holding AG from selling its Mircera anemia treatment in the U.S., while also upholding a ...

(CN) - The Federal Circuit refused to lift an injunction barring F. Hoffman-La Roche Ltd. from importing its anemia treatment, Mircera, to the United States, saying the drug infringes on some of Amgen ...

ZURICH , Switzerland The Food and Drug Administration has approved Roche Holdings’ new drug Mircera, which is used for the treatment of anemia associated with chronic renal failure in adults ...